EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Challenges and Strategies in Managing β-Lactam–Resistant Pseudomonas aeruginosa in China

Yue Li, Heng Cai, Xiaoting Hua iD, Yunsong Yu iD

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag033 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Yue Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, beta-Lactam Resistance, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

β-Lactam antibiotics are the cornerstone of therapy for Pseudomonas aeruginosa infections. Their effectiveness, however, has been increasingly compromised by antimicrobial resistance. This article presents a perspective on the evolving challenges and strategies associated with β-lactam resistance in P. aeruginosa, with a particular focus on China. The perspective was developed through a focused narrative review of recent clinical, epidemiological, and mechanistic studies. We first outline the current epidemiology of β-lactam–resistant P. aeruginosa, highlighting regional trends and the dissemination of high-risk clones. We then review the evolving β-lactam resistance mechanisms, emphasizing the prevalence and variety of carbapenemases. Finally, we discuss therapeutic strategies for managing resistant infections. This includes diagnostic advances, rational selection of novel β-lactam agents, dosing optimization, and combination regimens. Together, these insights provide a structured framework for understanding and managing β-lactam–resistant P. aeruginosa in contemporary clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPseudomonas Infectionsbeta-Lactam ResistanceAnti-Bacterial Agentsbeta-LactamsHumansChinabeta Lactam Antibioticsbeta-LactamasesBacterial Proteins

Stichwörter der Autor:innen

Pseudomonas aeruginosaantimicrobial resistancecarbapenemasetreatment optimizationβ-lactams

Substanzen

Anti-Bacterial Agentsbeta Lactam Antibioticsbeta-Lactamsbeta-LactamasesBacterial Proteinscarbapenemase

Autor:innen und Institutionen

  • Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Key Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China.
  • Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Xiaoting Hua, Yunsong Yu

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Li, Y., Cai, H., Hua, X., & Yu, Y. (2026). Challenges and Strategies in Managing β-Lactam–Resistant Pseudomonas aeruginosa in China. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag033

Vancouver

Li Y, Cai H, Hua X, Yu Y. Challenges and Strategies in Managing β-Lactam–Resistant Pseudomonas aeruginosa in China. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag033

BibTeX
@article{Li2026,
  author = {Li, Yue and Cai, Heng and Hua, Xiaoting and Yu, Yunsong},
  title = {Challenges and Strategies in Managing β-Lactam–Resistant Pseudomonas aeruginosa in China},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag033}
}
Kostenlos starten →